Strata Critical Medical: Significant Upside Potential Backed By Robust EBITDA Growth

AI Briefing

• – Strata Critical Medical rated Buy with 30–35% upside over 12–24 months
• – SRTA stock trades at a 53% EV/EBITDA discount to peer TMDX
• – Significant upside potential backed by robust EBITDA growth